XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Note 9 - Commitments and Contingencies (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Sep. 30, 2023
Sep. 22, 2023
Jan. 26, 2023
Feb. 07, 2022
Jan. 07, 2022
Jul. 12, 2021
Feb. 28, 2023
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Jun. 30, 2023
Sep. 21, 2023
May 11, 2023
Mar. 01, 2023
Capital Expenditures Incurred but Not yet Paid               $ 1,000,000            
Deconsolidation, Gain (Loss), Amount               0   $ 0        
Equity Securities, FV-NI               14,457,288 $ 18,318,521          
Equity Securities, FV-NI, Cost               $ 7,500,000            
Common Stock [Member]                            
Shares Issued, Price Per Share (in dollars per share)               $ 3.59            
Warrant [Member]                            
Shares Issued, Price Per Share (in dollars per share)               $ 0.06            
Special Purpose Acquisition Company (SPAC) [Member]                            
Financing Receivable, before Allowance for Credit Loss   $ 1,000,000                        
Murphy Canyon Acquisition Sponsor, LLC [Member]                            
Intangible Assets, Net (Excluding Goodwill)                         $ 5,000,001  
Investment Income, Net               $ 664,232            
Deconsolidation, Gain (Loss), Amount   6,200,000             $ 40,300,000          
Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount   $ 34,100,000                        
Conduit Pharmaceuticals Inc [Member]                            
Stock Issued During Period, Shares, New Issues (in shares)   754,000                        
Stock Issued During Period, Shares, Acquisitions (in shares)   65,000,000                        
Conduit Pharmaceuticals Inc [Member] | Director [Member]                            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 45,000 45,000                        
Stock Issued During Period, Shares, Issued for Services (in shares) 45,000 45,000                        
Conduit Pharmaceuticals Inc [Member] | Private Warrants [Member]                            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)   754,000                        
Conduit Pharmaceuticals Inc [Member] | Conversion of Class B to Class A Common Stock [Member]                            
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)   3,306,250                        
Common Class A [Member]                            
Stock Subject to Possible Redemption, Shares (in shares)                           2,187,728
Stock Issued During Period, Shares, New Issues (in shares)           1,000,000                
Common Class A [Member] | Conduit Pharmaceuticals Inc [Member] | Private Warrants [Member]                            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)   754,000                        
Trust for the SPAC Class A Common Stockholders [Member]                            
Cash Withdrawn From Trust Account                     $ 114,100,000      
Trust Account, Income Tax Withdraws             $ 200,050              
Trust Account, Extension Payments             $ 155,403              
Investments                     $ 23,300,000      
The “Merger Consideration” [Member]                            
Stock Redeemed or Called During Period, Shares (in shares)     11,037,272                      
Special Purpose Acquisition Company (SPAC) [Member]                            
Subsidiary, Ownership Percentage, Parent                       65.00%    
Conduit Pharmaceuticals Inc [Member]                            
Investment Owned, Net Assets, Percentage 6.50% 6.50%           6.30%            
SPAC, Initial Public Offering [Member] | Murphy Canyon Acquisition Sponsor, LLC [Member]                            
Proceeds from Issuance of Common Stock       $ 132,250,000 $ 132,250,000                  
Subsidiary, Ownership Percentage, Parent         23.50%                  
Units Issued During Period, Units, New Issues (in shares)       13,225,000 132,250,000                  
SPAC Units, Composition, Number of Shares Per Unit (in shares)         1                  
SPAC, Placement Units, Number of Units Purchased (in shares)       754,000                    
SPAC, Placement Units, Price Per Share (in dollars per share)       $ 10                    
SPAC, Purchase Units, Payments for the Purchase of Equity       $ 7,540,000                    
Stock Issuance Costs       7,738,161                    
Underwriting Discounts and Commission       2,645,000                    
Deferred Underwriting Fees       4,628,750                    
Other Equity Offering Costs       $ 464,411